Company: BLRX
Filing Date: 2025-04-11
Form Type: 424B5
Source: 0001178913-25-001282
Chunk: 0

Company: BioLineRx Ltd.
Filing Date: 2025-04-11
Form: 424B5
Chunk 0
---
#### Filed Pursuant to Rule 424(b)(5)

#### Registration No. 333-276323

#### PROSPECTUS SUPPLEMENT
**(To Prospectus Dated January 5, 2024)**

<div align='center'>**Up to $4,800,000 of 
 American Depositary Shares Representing Ordinary Shares**</div>

**This prospectus supplement amends and supplements certain information in the prospectus, dated January 5, 2024, or the ATM Prospectus, filed with the Securities and Exchange
      Commission as part of our registration statement on Form F-3 (333-276323) relating to the offer and sale of American Depositary Shares, or ADSs, representing our ordinary shares, par value NIS 0.10 per share, from time to time pursuant to the terms
      of the at-the-market offering agreement, or the Offering Agreement, dated September 3, 2021, with H.C. Wainwright & Co., LLC,  or the Sales Agent. This prospectus supplement should be read in conjunction with the ATM Prospectus, and is qualified
      by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with,
      the ATM Prospectus, and any future amendments or supplements thereto.

On March 31, 2025, upon filing our Annual Report on Form 20-F for the fiscal year ended December 31, 2024, we became subject to the offering limits in General Instruction I.B.5 of
      Form F-3. As of the date of this prospectus supplement, the aggregate market value of our outstanding voting and non-voting common equity held by non-affiliates pursuant to General Instruction I.B.5 of Form F-3 is $14,562,368, which was calculated
      based on a price of $4.11 per share, the closing price of our ADSs on February 18, 2025, which is the highest closing sale price of our ADSs on the Nasdaq Capital Market within the prior 60 days. During the prior 12 calendar month period that ends
      on, and includes, the date of this prospectus supplement, we have not sold any sold securities pursuant to General Instruction I.B.5 of Form F-3. Pursuant to General Instruction I.B.5